<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568723</url>
  </required_header>
  <id_info>
    <org_study_id>11-006510</org_study_id>
    <secondary_id>U54CA163004</secondary_id>
    <nct_id>NCT01568723</nct_id>
  </id_info>
  <brief_title>Betrnet Stem Cells and the Origins of Barrett's Esophagus Project 3 RF Ablation</brief_title>
  <acronym>BetrnetRF</acronym>
  <official_title>Stem Cells And The Origins Of Barrett's Esophagus:Identification Of Novel Biomarkers And Gene Signatures In Barrett's Esophagus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine biomarkers which can predict response to ablation
      therapy in patients with Barretts esophagus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Project is designed to identify biologically-based and clinically-useful biomarkers of
      tissue at risk for neoplastic progression as well as of response to ablation therapy. These
      results will result in improved risk stratification in BE and better targeting of resources
      for patients who are candidates for ablative therapy, while simultaneously providing key
      information regarding the origins of Barrett's esophagus.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response to therapy</measure>
    <time_frame>one year post ablation</time_frame>
    <description>evaulation will be made at 3 month intervals for one year post ablation</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">125</enrollment>
  <condition>Barrett's Esophagus</condition>
  <arm_group>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
    <description>participants with barrett's esophagus with high grade dysplasia who undergo radiofrequency ablation (RFA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>response to therapy</intervention_name>
    <description>evaluate specific markers for response to therapy at specific intervals pre and post therapy</description>
    <arm_group_label>Radiofrequency ablation</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      biopsy samples, serum, plasma, buffycoat, cytology brushings
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants must have biopsy proven Barret's esophgus with evidence of specialized
        intestinal epithelium with high grade dysplasia or early intramucosal carcinoma (mEAC) on
        histology (confirmed by two pathologists). Patients must have a BE length ≥ 2 cm and ≤ 8
        cm.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Barrett's esophagus with high grade dysplasia or intramucosal (early) adenocarcinoma.

          -  BE length ≥ 2 cm and ≤ 8 cm.

          -  Able to return every 3 months for one year after ablation

        Exclusion Criteria:

          -  Patients who are unable to be compliant with follow-up endoscopies

          -  patients who cannot tolerate Proton Pump inhibitors

          -  pre-existing esophageal strictures

          -  pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth K Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Kenneth K. Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Barrett's esophagus</keyword>
  <keyword>high grade dysplasia</keyword>
  <keyword>ablation</keyword>
  <keyword>radiofrequency ablation</keyword>
  <keyword>esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

